糖尿病并发症对重型创伤性脑损伤患者的影响
该回顾性队列研究利用TriNetX数据库,将重型TBI患者分为无糖尿病、无并发症DM和复杂DM三组。复杂DM组5893例与匹配的无DM对照相比,90天全因死亡率显著升高(33.8% vs 29.7%;OR 1.21;95%CI 1.12-1.30),30天再入院及多种全身并发症风险亦增加。无并发症DM组3914例结局与无DM对照相当,死亡率无显著差异(27.9% vs 28.4%;OR 0.98)。结论提示伤前糖尿病微血管并发症决定TBI后生理储备,应将DM视为谱系疾病而非单一诊断。
要点
- 复杂DM组重型TBI患者90天死亡率33.8%,显著高于匹配无DM组的29.7%(OR 1.21;95%CI 1.12-1.30;P<0.001)。
- 复杂DM组30天再入院风险增加(OR 1.45),急性肾损伤(OR 1.29)、脓毒症(OR 1.23)、肺炎(OR 1.13)、癫痫(OR 1.18)、脑梗死(OR 1.30)风险均升高。
- 复杂DM组需延长插管/气管切开(OR 1.40)及神经重症干预(OR 1.50)的风险更高,CAUTI(OR 1.92)和CLABSI(OR 1.91)风险亦显著增加。
- 无并发症DM组死亡率与无DM组相当(27.9% vs 28.4%;OR 0.98;P=0.651),生存率相似(HR 0.93;95%CI 0.85-1.02;P=0.168)。
- 无并发症DM组30天再入院风险低于无DM组(OR 0.85;P=0.002),其余多数并发症发生率相当。
适用人群与场景
- 纳入:重型创伤性脑损伤患者,分为无糖尿病、无并发症糖尿病和复杂糖尿病三组,复杂DM组5893例、无并发症DM组3914例与匹配的无DM对照比较。
- 排除:原文未提及具体排除标准。
- 场景:未明确限定急诊、ICU或院前,基于TriNetX数据库的住院患者数据。
诊断标准与关键阈值
- 糖尿病分层:无糖尿病、无并发症DM、复杂DM(存在伤前糖尿病并发症)。
- 主要结局:90天全因死亡率、30天再入院、继发性全身并发症。
处置流程与药物剂量
- 原文未提及
红旗征与不能漏的情况
- 复杂DM患者伤前存在糖尿病并发症时,重型TBI后死亡、再入院及全身并发症风险显著增加,需警惕急性肾损伤、脓毒症、肺炎、癫痫、脑梗死等。
- 复杂DM患者神经重症干预(OR 1.50)及延长插管/气管切开(OR 1.40)风险更高。
- 复杂DM患者CAUTI(OR 1.92)和CLABSI(OR 1.91)风险显著增加,需关注导管相关感染。
研究设计与关键结果
- 研究类型:回顾性队列研究,利用TriNetX数据库;样本量:复杂DM组5893例,无并发症DM组3914例,并与匹配的无DM对照比较;人群:重型TBI患者。
- 主要终点:复杂DM组90天全因死亡率33.8% vs 无DM组29.7%(OR 1.21;95%CI 1.12-1.30;P<0.001),生存率更差(HR 1.22;95%CI 1.15-1.30;P<0.001)。
- 关键次要终点:复杂DM组30天再入院OR 1.45,急性肾损伤OR 1.29,脓毒症OR 1.23,肺炎OR 1.13,癫痫OR 1.18,脑梗死OR 1.30,延长插管/气管切开OR 1.40,神经重症干预OR 1.50,CAUTI OR 1.92,CLABSI OR 1.91(均P<0.05)。
- 无并发症DM组 vs 无DM组:死亡率27.9% vs 28.4%(OR 0.98;P=0.651),生存率HR 0.93(95%CI 0.85-1.02;P=0.168),30天再入院OR 0.85(P=0.002),其余多数并发症相当。
证据类型、等级与局限
- 证据类型:回顾性队列研究。
- 局限:原文未明确提及,但设计本身为回顾性、基于数据库(TriNetX),可能存在混杂和选择偏倚。
对床旁实践的改变
- 对重型TBI患者,应区分有无伤前糖尿病并发症,而非仅关注糖尿病诊断;复杂DM患者死亡率及并发症风险更高,需加强监测和预防措施。
- 无并发症DM患者的重型TBI结局与无DM者相当,提示不必因单纯DM诊断而过度调整治疗强度。
- 复杂DM患者需关注急性肾损伤、脓毒症、肺炎、癫痫、脑梗死及导管相关感染(CAUTI、CLABSI)的预防和早期识别。
- 原文未提及具体治疗改变,以上为基于研究结果的提示。
指南或共识出处
- 原文未提及
以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: The impact of diabetes mellitus (DM) on severe traumatic brain injury (TBI) outcomes remains poorly defined, with prior studies treating DM as a monolithic diagnosis. We hypothesized that post-TBI mortality is severity dependent, driven by preexisting diabetic complications rather than the diagnosis of DM alone.
METHODS: Retrospective cohort study utilized TriNetX. Patients with severe TBI were stratified into three cohorts: non-diabetic, uncomplicated DM, and complicated DM. Primary outcomes included: 90-day all-cause mortality, 30-day readmission, and secondary systemic complications.
RESULTS: A total of 5893 patients with complicated DM and 3914 with uncomplicated DM were compared with matched non-diabetic controls. Patients with complicated DM had significantly higher mortality (33.8% vs. 29.7%; OR 1.21; 95% CI 1.12-1.30; P < 0.001), worse survival (HR 1.22; 95% CI 1.15-1.30; P < 0.001), and increased risks of 30-day readmission (OR 1.45), acute kidney injury (OR 1.29), sepsis (OR 1.23), pneumonia (OR 1.13), seizures (OR 1.18), cerebral infarction (OR 1.30), prolonged intubation/tracheostomy (OR 1.40), neurocritical care interventions (OR 1.50), catheter-associated urinary tract infection (CAUTI) (OR 1.92), and central line-associated bloodstream infection (CLABSI) (OR 1.91) (all P < 0.05). In contrast, patients with uncomplicated DM demonstrated outcomes comparable to non-diabetic controls, with no increased mortality (27.9% vs. 28.4%; OR 0.98; P = 0.651), similar survival (HR 0.93; 95% CI 0.85-1.02; P = 0.168), and comparable rates of most complications, though they had lower 30-day readmission (OR 0.85; P = 0.002).
CONCLUSIONS: Severe TBI outcomes are critically dependent on preinjury diabetic complications, with the increased morbidity and mortality confined to preexisting complications. These findings reframe DM as a spectrum where microvascular integrity determines physiological resilience following neurological trauma.
参考来源
- Seifi A, Chui CK, Villahermosa A, et al. Impact of Complicated Diabetes Mellitus in Patients Following Severe Traumatic Brain Injury. Neurocrit Care. 2026. PMID: 42426346. doi:10.1007/s12028-026-02585-1
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。